Alumis Inc. (NASDAQ:ALMS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Alumis Inc. (NASDAQ:ALMS) has received an average rating of “Moderate Buy” from the twelve analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $40.30.

A number of equities research analysts have recently weighed in on the company. Raymond James Financial assumed coverage on Alumis in a research note on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 target price for the company. HC Wainwright lowered Alumis from a “buy” rating to a “neutral” rating and set a $25.00 target price for the company. in a research note on Friday, May 15th. Chardan Capital boosted their target price on Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Loop Capital set a $37.00 target price on Alumis in a research note on Wednesday, January 21st. Finally, Oppenheimer boosted their target price on Alumis from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Monday, March 30th.

Alumis Trading Up 1.7%

ALMS opened at $21.52 on Friday. Alumis has a 12-month low of $2.76 and a 12-month high of $30.60. The stock has a 50-day moving average price of $24.20 and a 200-day moving average price of $19.31. The stock has a market capitalization of $2.74 billion, a P/E ratio of -10.87 and a beta of -0.31.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The company had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. On average, equities research analysts predict that Alumis will post -2.89 EPS for the current year.

More Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Chardan Capital raised its price target on Alumis to $40 from $38 and kept a Buy rating, signaling strong upside potential for the stock. Chardan price target raise via Benzinga
• Positive Sentiment: HC Wainwright lifted several earnings estimates for Alumis, including Q2 2026, Q3 2026, Q4 2026, FY2026, and FY2027, which suggests modestly improving expectations for the business. HC Wainwright estimate updates
• Neutral Sentiment: HC Wainwright maintained a Neutral rating with a $25 price target, which is less bullish than Chardan’s view and may temper enthusiasm. HC Wainwright coverage
• Neutral Sentiment: Recent research coverage and forecast updates appear to be the main catalyst, rather than any new operational announcement or clinical update from Alumis. Alumis consensus estimates
• Negative Sentiment: Despite the analyst support, Alumis continues to be expected to report losses across 2026 and 2027, so fundamental profitability remains a risk factor for the stock. Alumis earnings estimates

Institutional Investors Weigh In On Alumis

A number of hedge funds and other institutional investors have recently modified their holdings of ALMS. AXQ Capital LP bought a new position in Alumis during the 3rd quarter valued at approximately $78,000. Inscription Capital LLC bought a new position in Alumis during the 3rd quarter valued at approximately $82,000. Grange Capital LLC bought a new position in Alumis during the 4th quarter valued at approximately $312,000. CWM LLC raised its position in Alumis by 1,028.7% during the 3rd quarter. CWM LLC now owns 10,384 shares of the company’s stock valued at $41,000 after purchasing an additional 9,464 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new position in Alumis during the 1st quarter valued at approximately $23,309,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.